Savatril Tablet 24 mg+26 mg combines Sacubitril 24 mg and Valsartan 26 mg, forming a potent therapy used in the management of heart failure with reduced ejection fraction (HFrEF). This dual-action medication works by both enhancing protective neurohormonal pathways and inhibiting harmful effects on the cardiovascular system, helping improve heart function, reduce hospitalization, and enhance quality of life in patients with chronic heart failure.

Sacubitril is a neprilysin inhibitor that prevents the breakdown of natriuretic peptides, promoting vasodilation, natriuresis, and diuresis. Valsartan is an angiotensin II receptor blocker (ARB) that inhibits the harmful effects of the renin-angiotensin-aldosterone system (RAAS), reducing vasoconstriction, sodium retention, and cardiac remodeling. Together, they provide a synergistic effect for optimal heart failure management.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition

• Sacubitril 24 mg

• Valsartan 26 mg

Mechanism of Action

Sacubitril + Valsartan acts through a dual mechanism:

1. Sacubitril (Neprilysin Inhibitor):

   • Inhibits neprilysin, an enzyme responsible for breaking down natriuretic peptides

   • Increases levels of natriuretic peptides, leading to vasodilation, diuresis, and reduced cardiac stress

   • Helps decrease fluid overload and cardiac remodeling

2. Valsartan (Angiotensin II Receptor Blocker):

   • Blocks angiotensin II from binding to its receptor

   • Reduces vasoconstriction and aldosterone-mediated sodium and water retention

   • Lowers blood pressure and decreases cardiac workload

The combination improves cardiac output, reduces ventricular strain, and lowers the risk of heart failure-related hospitalizations.

Indications

Savatril Tablet 24 mg+26 mg is indicated for:

• Chronic heart failure with reduced ejection fraction (HFrEF)

• Patients with NYHA class II–IV symptoms requiring neurohormonal blockade

• Reduction of cardiovascular mortality and hospitalization due to heart failure

It is intended for use under the guidance of a cardiologist or a physician experienced in managing heart failure.

Dosage and Administration

• The usual starting dose is 24 mg Sacubitril + 26 mg Valsartan twice daily, with adjustments based on blood pressure, kidney function, and tolerability.

• Tablets should be taken orally with or without food, preferably at the same times each day.

• Patients switching from ACE inhibitors must have a washout period of at least 36 hours to reduce the risk of angioedema.

Regular monitoring of blood pressure, kidney function, and electrolytes is recommended during therapy.

Benefits

• Reduces hospitalization risk in chronic heart failure

• Improves symptoms such as fatigue, shortness of breath, and fluid retention

• Enhances cardiac function and ventricular remodeling

• Provides dual neurohormonal modulation for better heart protection

• Convenient oral dosing with twice-daily administration

Precautions

• Contraindicated in patients with a history of angioedema related to ACE inhibitors or ARBs

• Use with caution in patients with severe renal or hepatic impairment

• Monitor potassium and renal function, as hyperkalemia may occur

• Avoid use during pregnancy and breastfeeding

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Possible Side Effects

Common side effects include:

• Low blood pressure (hypotension)

• Dizziness or lightheadedness

• Elevated potassium levels

• Cough or mild gastrointestinal disturbances

Rare but serious adverse effects may include angioedema, kidney dysfunction, or severe hypotension. Immediate medical attention is necessary if these occur.

Storage

Store below 30°C in a dry, cool place, protected from light. Keep out of reach of children and ensure the blister pack remains intact until use.

Savatril Tablet 24 mg+26 mg offers an effective and comprehensive therapy for heart failure patients, combining Sacubitril and Valsartan to improve cardiac function, reduce hospitalizations, and enhance overall quality of life.